Bipolar androgen therapy plus olaparib in men with metastatic castration-resistant prostate cancer
Michael T. Schweizer, Roman Gulati, Todd Yezefski, Heather H. Cheng, Elahe A. Mostaghel, Michael C. Haffner, Radhika A. Patel, Navonil De Sarkar, Gavin Ha, Ruth F. Dumpit, Brianna Woo, Aaron Lin, Patrick Panlasigui, Nerina McDonald, Michael M. C. Lai, Katie Nega, Jeannette Hammond, Petros Grivas, Andrew C. Hsieh, Bruce Montgomery, Peter S. Nelson, Evan Y. Yu
Topics & Concepts
MedicineOlaparibProstate cancerEnzalutamideCohortInternal medicineAndrogen deprivation therapyOncologyPARP inhibitorProgression-free survivalCancerAndrogen receptorChemotherapyPoly ADP ribose polymerasePolymeraseBiochemistryChemistryGeneProstate Cancer Treatment and ResearchProstate Cancer Diagnosis and TreatmentPARP inhibition in cancer therapy